• Patient Site
  • Peyronie's Disease
  • Plantar Fibromatosis
  • Dupuytren's Disease
• Healthcare Professionals

Conference Calendar

PDLabs will be attending the following conferences in 2008. Please visit us at the exhibits.

March 2008

AUA Southeastern Section Annual Meeting
March 6th - 9th
Booth #408

Midwest Podiatry Conference
March 27th - 30th
Booth #607

April 2008

TPMA Spring Conference
April 11th - 13th
Booth #209

May 2008

AUA Annual Meeting
May 17th - 20th
Booth #1302

June 2008

The Western Podiatric Medical Conference
June 19th - 22nd
Booth #328

July 2008

APMA Annual Meeting
July 24th - 27th
Booth #613

August 2008

FUS
August 29th - 31st

September 2008

AUA North Eastern Section Annual Meeting
September 17th - 20th
Booth #21

AUA South Central Annual Meeting
September 18th - 21st

TPMA Southwest Foot & Ankle Conference
September 12th - 13th

AUA North Central Section Annual Meeting
September 24th - 27th

AUA Mid-Atlantic Section Annual Meeting
September 25th - 28th
Booth #T34

October 2008

AUA Western Section Annual Meeting
October 28th – November 1st

Copyright © 2007 PDLabs Inc. All rights reserved. Privacy Policy.

The information contained in this website is provided for educational purposes only and is not intended to replace discussions with your healthcare provider. All decisions regarding a patients' treatment must be made with a healthcare provider.

Transdermal Verapamil 15% Gel is available as a compounded medication exclusively from PDLabs. Transdermal Verapamil 15% Gel is not FDA approved. PDLabs is not an "internet pharmacy" and requires that an appropriate doctor-patient-pharmacist relationship be maintained. PDLabs will not fill prescriptions for patients that do not have a valid patient-doctor relationship.

Transdermal Verapamil 15% Gel is not for everyone. Patients with specific heart conditions known as atrioventricular (AV) block or Sino-Atrial (SA) block should not use calcium channel blockers such as verapamil. Patients taking the antiarrhythmic drug Tikosyn® (Dofetilide) should not use Transdermal Verapamil 15% Gel.

Patients taking digoxin or cyclosporine should have their drug levels monitored on a regular basis as verapamil may decrease the metabolism and clearance of these drugs. Patients taking antiarrhythmic drugs should consult with their doctor before taking Transdermal Verapamil 15% Gel to ensure it is safe to use. A PDLabs pharmacist can help with this discussion.

The most common side effect reported with Transdermal Verapamil 15% Gel, affecting 3-5% of Peyronie's disease patients, is varying degrees of skin irritation. Some patients using the medication for the first time may experience mild itching/irritation during the first few days of treatment. This is normal and usually resolves within 3-4 days. Other patients may experience more severe contact dermatitis, including itching, burning, redness, or swelling. More persistent or severe irritation can usually be treated with topical corticosteroids. Based on the individual symptoms, PDLabs will work with the patient and prescribing physician to determine the best course of treatment to resolve irritation.